These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30994869)

  • 1. 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention.
    Grundy SM; Stone NJ
    JAMA Cardiol; 2019 Jun; 4(6):589-591. PubMed ID: 30994869
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.
    Sabatine MS; Giugliano RP
    JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310
    [No Abstract]   [Full Text] [Related]  

  • 3. New Studies Do Not Challenge the American College of Cardiology/American Heart Association Lipid Guidelines.
    Hofer TP; Sussman JB; Hayward RA
    Ann Intern Med; 2016 May; 164(10):683-4. PubMed ID: 26857151
    [No Abstract]   [Full Text] [Related]  

  • 4. Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol.
    Chuzi S; Pfenniger A; Lloyd-Jones DM; Blumenthal RS; Smith SC; Virani SS; Grundy SM; Stone NJ
    JAMA Cardiol; 2019 May; 4(5):473-477. PubMed ID: 30969319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?
    Thanassoulis G; Gregoire J; Pearson GJ
    Can J Cardiol; 2019 May; 35(5):558-563. PubMed ID: 31030858
    [No Abstract]   [Full Text] [Related]  

  • 6. A practical approach to the cholesterol guidelines and ASCVD prevention.
    Cho L
    Cleve Clin J Med; 2020 May; 87(5 suppl 1):15-20. PubMed ID: 32349970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know.
    Jia X; Al Rifai M; Birnbaum Y; Smith SC; Virani SS
    Curr Atheroscler Rep; 2019 Apr; 21(6):20. PubMed ID: 30941517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk.
    Tokgözoğlu L; Casula M; Pirillo A; Catapano AL
    Atheroscler Suppl; 2020 Dec; 42():e1-e5. PubMed ID: 33589218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Grundy SM; Stone NJ; Bailey AL; Beam C; Birtcher KK; Blumenthal RS; Braun LT; de Ferranti S; Faiella-Tommasino J; Forman DE; Goldberg R; Heidenreich PA; Hlatky MA; Jones DW; Lloyd-Jones D; Lopez-Pajares N; Ndumele CE; Orringer CE; Peralta CA; Saseen JJ; Smith SC; Sperling L; Virani SS; Yeboah J
    J Am Coll Cardiol; 2019 Jun; 73(24):e285-e350. PubMed ID: 30423393
    [No Abstract]   [Full Text] [Related]  

  • 10. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Grundy SM; Stone NJ; Bailey AL; Beam C; Birtcher KK; Blumenthal RS; Braun LT; de Ferranti S; Faiella-Tommasino J; Forman DE; Goldberg R; Heidenreich PA; Hlatky MA; Jones DW; Lloyd-Jones D; Lopez-Pajares N; Ndumele CE; Orringer CE; Peralta CA; Saseen JJ; Smith SC; Sperling L; Virani SS; Yeboah J
    J Am Coll Cardiol; 2019 Jun; 73(24):3168-3209. PubMed ID: 30423391
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
    Lloyd-Jones DM
    JAMA Cardiol; 2017 Sep; 2(9):937-938. PubMed ID: 28768306
    [No Abstract]   [Full Text] [Related]  

  • 12. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
    O'Keefe JH; DiNicolantonio JJ; Lavie CJ
    Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
    Ioannidis JPA
    JAMA; 2017 Aug; 318(5):419-420. PubMed ID: 28738115
    [No Abstract]   [Full Text] [Related]  

  • 14. 2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline.
    Grundy SM; Stone NJ;
    Ann Intern Med; 2019 Jun; 170(11):779-783. PubMed ID: 31132793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
    Ortega Martínez de Victoria E
    Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
    Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
    Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
    ; Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
    J Am Coll Cardiol; 2016 Jul; 68(1):92-125. PubMed ID: 27046161
    [No Abstract]   [Full Text] [Related]  

  • 20. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.